SEP 01, 2022 3:00 AM PDT

Pre-clinical Study Describes a Strategy to Improve Adoptive Cell Therapy

WRITTEN BY: Katie Kokolus

Immune cells, known as T cells (also called T lymphocytes), play a vital role in the anti-tumor immune response.  T cells find, attack, and, when effective, kill cancer cells.  Adoptive cell transfer (ACT), also called adoptive cell therapy, describes a form of cancer immunotherapy carried out by administering T cells to patients, providing them with an arsenal of killer cells. 

T cells use a protein present on their surface called a T cell receptor (TCR) to identify cancer cells.  Cancer cells express a protein on their surface called an antigen , and when a TCR binds an antigen, the T cell becomes activated to kill the cancer cell.  An integral part of this system is regulated because each TCR recognizes a specific antigen.  Immunity is most robust if a patient has a high number of T cells possessing TCRs programmed to find the antigen on their cancer.  

In some situations, doctors can evaluate the specific antigen present on a patient’s cancer cells.  In such a case, it may be possible to capitalize on the TCR’s role in activating the anti-tumor immune response by administering the patient T cells engineered to express antigen-specific TCRs.  This method of ACT utilizing specially engineered TCRs has some efficacy as a cancer therapy, particularly in some types of melanoma.  Unfortunately, immunosuppressive factors in the tumor microenvironment (TME) can limit the effectiveness of engineered T cells.

A recent study in Science Immunology provides new evidence on overcoming an immunosuppressive TME that allows ACT to work more effectively.  This work focuses on a highly specialized subset of NKT cells, immune cells which perform functions of both T cells and natural killer (NK) cells.  The cells utilized in this study, called invariant NK T (iNKT) cells, limit the functions of suppressive cells in the TME. 

The researchers engineered iNKT cells to express a specialized TCR.  When transferred into mice, the TCR-engineered iNKT cells proved more effective in controlling tumors than unmodified iNKT cells or T cells engineered with the same TCR. The study found that the TCR-engineered iNKT cells both killed cancer cells and reduced the activities of the immunosuppressive cells in the TME.   The authors then utilized a multistage vector platform which ensured delivery of the transferred cells to the tumor.  This drug delivery enhancement, combined with an iNKT agonist, improved both anti-tumor functions. 

The authors conclude that harnessing the dual functions of iNKT cells to attack cancer cells and simultaneously hinder immunosuppressive cells could become a novel ACT strategy.

 

Sources: Nature, Science Immunology

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 21, 2022
Cancer
The Legacy of Lady Mary Wortley Montagu
AUG 21, 2022
The Legacy of Lady Mary Wortley Montagu
Today, August 21, marks the 260th anniversary of the passing of a pioneer in the medical field.  In 1762, Lady Mary ...
SEP 12, 2022
Cancer
Novel Method to Detect Cancer with a Blood Screen Demonstrates Feasibility
SEP 12, 2022
Novel Method to Detect Cancer with a Blood Screen Demonstrates Feasibility
Early detection of cancer benefits patients with almost all cancer types.  Late-stage tumors remain more difficult ...
NOV 13, 2022
Microbiology
A Cancer-Linked Microbe Can Use a Dietary Nutrient to Survive
NOV 13, 2022
A Cancer-Linked Microbe Can Use a Dietary Nutrient to Survive
The microbes in the human gastrointestinal tract, known as the gut microbiome, have a significant impact on out health a ...
NOV 17, 2022
Drug Discovery & Development
Implantable Pump Delivers Chemotherapy Directly to the Brain
NOV 17, 2022
Implantable Pump Delivers Chemotherapy Directly to the Brain
An implantable pump can bypass the blood-brain barrier and deliver chemotherapy to specific brain areas. The correspondi ...
NOV 19, 2022
Clinical & Molecular DX
New Research Shows How Bacteria Could Help Tumors Progress and Resist Treatment
NOV 19, 2022
New Research Shows How Bacteria Could Help Tumors Progress and Resist Treatment
New research from the Fred Hutchinson Cancer Center in Seattle postulates that certain bacteria significantly impact the ...
NOV 23, 2022
Technology
Hyperthermic Nanoparticles for Cancer Treatment
NOV 23, 2022
Hyperthermic Nanoparticles for Cancer Treatment
Hyperthermia (excess heats) refers to the use of high temperatures to treat cancer. When used to treat tumors locally, h ...
Loading Comments...